Advances/NNS
in/IN
Serological/JJ
Diagnosis/NN
of/IN
Taenia/NN
solium/NN
Neurocysticercosis/NN
in/IN
Korea/NN
./.
====================
Cysticercosis/NN
,/,
a/DT
parasitic/JJ
disease/NN
caused/VBD
by/IN
Taenia/NN
solium/NN
metacestode/NN
(/(
TsM/NN
)/)
,/,
has/VBZ
a/DT
major/JJ
global/JJ
public/JJ
health/NN
impact/NN
in/IN
terms/NNS
of/IN
disability-adjusted/JJ
life/NN
years/NNS
./.
====================
The/DT
parasite/NN
preferentially/RB
infects/VBZ
subcutaneous/JJ
tissue/NN
,/,
but/CC
may/MD
invade/VB
the/DT
central/JJ
nervous/JJ
system/NN
,/,
resulting/VBG
in/IN
neurocysticercosis/NN
(/(
NC/NN
)/)
./.
====================
NC/NN
is/VBZ
an/DT
important/JJ
neglected/JJ
tropical/JJ
disease/NN
and/CC
an/DT
emerging/VBG
disease/NN
in/IN
industrialized/VBN
countries/NNS
due/JJ
to/TO
immigration/NN
from/IN
endemic/JJ
areas/NNS
./.
====================
The/DT
prevalence/NN
of/IN
taeniasis/NN
in/IN
Korea/NN
declined/VBD
from/IN
0.3/CD
%/NN
–12.7/CD
%/NN
during/IN
the/DT
1970s/NN
to/TO
below/IN
0.02/CD
%/NN
since/IN
the/DT
2000s/NN
./.
====================
A/DT
survey/NN
conducted/VBN
from/IN
1993/CD
to/TO
2006/CD
revealed/VBD
that/IN
the/DT
percentage/NN
of/IN
tested/VBN
samples/NNS
with/IN
high/JJ
levels/NNS
of/IN
specific/JJ
anti-TsM/JJ
antibody/NN
declined/VBD
from/IN
8.3/CD
%/NN
to/TO
2.2/CD
%/NN
,/,
suggesting/VBG
the/DT
continuing/VBG
occurrence/NN
of/IN
NC/NN
in/IN
Korea/NN
./.
====================
Modern/NN
imaging/VBG
modalities/NNS
have/VBP
substantially/RB
improved/VBD
the/DT
diagnostic/JJ
accuracy/NN
of/IN
NC/NN
,/,
and/CC
recent/JJ
advances/NNS
in/IN
the/DT
molecular/JJ
biochemical/JJ
characterization/NN
of/IN
the/DT
TsM/NN
cyst/NN
fluid/NN
proteome/NN
also/RB
significantly/RB
strengthened/JJ
NC/NN
serodiagnosis/NN
./.
====================
Two/CD
glycoproteins/NNS
of/IN
150/CD
and/CC
120/CD
kDa/NN
that/WDT
induce/VBP
strong/JJ
antibody/NN
responses/NNS
against/IN
sera/NNS
from/IN
patients/NNS
with/IN
active-stage/NN
NC/NN
have/VBP
been/VBN
elucidated/VBN
./.
====================
The/DT
150/CD
kDa/NN
protein/NN
showed/VBD
hydrophobic-ligand/NN
binding/NN
activities/NNS
and/CC
might/MD
be/VB
critically/RB
involved/VBN
in/IN
the/DT
acquisition/NN
of/IN
host-derived/JJ
lipid/NN
molecules/NNS
./.
====================
Fasciclin/NN
and/CC
endophilin/NN
B1/NN
,/,
both/CC
of/IN
which/WDT
play/VBP
roles/NNS
in/IN
the/DT
homeostatic/JJ
functions/NNS
of/IN
TsM/NN
,/,
showed/VBD
fairly/RB
high/JJ
antibody/NN
responses/NNS
against/IN
calcified/JJ
NC/NN
cases/NNS
./.
====================
NC/NN
is/VBZ
now/RB
controllable/JJ
and/CC
manageable/JJ
./.
====================
Further/RB
studies/NNS
should/MD
focus/VB
on/IN
controlling/VBG
late-onset/NN
intractable/JJ
seizures/VBZ
and/CC
serological/JJ
diagnosis/NN
of/IN
NC/NN
patients/NNS
infected/JJ
with/IN
few/JJ
worms/NNS
./.
====================
This/DT
article/NN
briefly/RB
overviews/VBZ
diagnostic/JJ
approaches/NNS
and/CC
discusses/VBZ
current/JJ
issues/NNS
relating/VBG
to/TO
NC/NN
serodiagnosis/NN
./.
====================
Cysticercosis/NN
is/VBZ
a/DT
parasitic/JJ
disease/NN
caused/VBD
by/IN
infection/NN
with/IN
the/DT
larval/JJ
stage/NN
of/IN
the/DT
cyclophyllidean/JJ
tapeworm/NN
Taenia/NN
solium/NN
./.
====================
The/DT
T./FW
solium/NN
metacestode/NN
(/(
TsM/NN
)/)
preferentially/RB
lodges/VBZ
in/IN
subcutaneous/JJ
tissues/NNS
and/CC
muscles/NNS
,/,
but/CC
often/RB
invades/VBZ
the/DT
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
,/,
resulting/VBG
in/IN
neurocysticercosis/NN
(/(
NC/NN
)/)
./.
====================
NC/NN
,/,
which/WDT
is/VBZ
a/DT
leading/VBG
cause/VBP
of/IN
adult-onset/JJ
seizure/NN
disorder/NN
,/,
is/VBZ
a/DT
major/JJ
global/JJ
public/JJ
health/NN
concern/NN
in/IN
several/JJ
endemic/JJ
areas/NNS
[/(
1/CD
]/)
./.
====================
Annually/RB
,/,
NC/NN
causes/VBZ
approximately/RB
28,000/CD
deaths/NNS
and/CC
more/RBR
than/IN
three/CD
million/NN
people/NN
are/VBP
at/IN
risk/NN
[/(
2/CD
]/)
./.
====================
In/IN
endemic/JJ
areas/NNS
of/IN
Latin/JJ
America/NN
and/CC
Africa/NNP
,/,
NC/NN
accounts/NNS
for/IN
10/CD
%/NN
–12/NN
%/NN
of/IN
all/DT
hospital/JJ
admissions/NNS
to/TO
neurological/JJ
departments/NNS
[/(
3/CD
]/)
./.
====================
NC/NN
is/VBZ
becoming/VBG
an/DT
emerging/VBG
or/CC
a/DT
re-emerging/JJ
disease/NN
in/IN
industrialized/VBN
countries/NNS
,/,
due/JJ
to/TO
the/DT
high/JJ
frequency/NN
of/IN
immigration/NN
from/IN
endemic/JJ
areas/NNS
./.
====================
Moreover/RB
,/,
NC/NN
is/VBZ
now/RB
regarded/VBN
as/IN
one/CD
of/IN
the/DT
most/JJS
important/JJ
food-borne/NN
zoonotic/JJ
helminthiases/VBZ
[/(
4/CD
]/)
./.
====================
Historically/RB
,/,
taeniasis/NN
and/CC
cysticercosis/NN
have/VBP
posed/VBN
formidable/JJ
public/JJ
health/NN
problems/NNS
in/IN
Korea/NN
./.
====================
In/IN
the/DT
1970s/NN
,/,
the/DT
prevalence/NN
of/IN
taeniasis/NN
was/VBD
0.3/CD
%/NN
–12.7/CD
%/NN
according/VBG
to/TO
stool/NN
examinations/NNS
and/CC
4.5/CD
%/NN
–38.0/CD
%/NN
by/IN
questionnaire/NN
surveys/NNS
[/(
5/CD
]/)
./.
====================
However/RB
,/,
the/DT
prevalence/NN
is/VBZ
currently/RB
below/IN
0.02/CD
%/NN
,/,
and/CC
most/JJS
affected/VBN
patients/NNS
are/VBP
elderly/JJ
and/CC
originate/VBP
from/IN
remote/JJ
islands/VBZ
[/(
6/CD
]/)
./.
====================
From/IN
1987/CD
to/TO
1990/CD
,/,
a/DT
survey/NN
investigated/VBD
the/DT
seroprevalence/NN
of/IN
NC/NN
in/IN
mixed/JJ
epilepsy/NN
patients/NNS
in/IN
Korea/NN
./.
====================
A/DT
total/JJ
of/IN
2667/CD
serum/NN
samples/NNS
,/,
randomly/RB
selected/VBN
from/IN
27/CD
different/JJ
localities/NNS
,/,
were/VBD
tested/VBN
for/IN
their/PRP$
specific/JJ
antibody/NN
levels/NNS
by/IN
enzyme-linked/JJ
immunosorbent/JJ
assay/NN
(/(
ELISA/NN
)/)
./.
====================
The/DT
positivity/NN
rate/NN
was/VBD
4.0/CD
%/NN
in/IN
the/DT
patient/NN
group/NN
(/(
standardized/VBN
positivity/NN
rate/NN
,/,
3.1/CD
%/NN
)/)
and/CC
2.1/CD
%/NN
in/IN
persons/NNS
without/IN
mixed/JJ
epilepsy/NN
(/(
standardized/VBN
rate/NN
:/:
1.8/CD
%/NN
)/)
./.
====================
Geographically/RB
,/,
the/DT
rate/NN
was/VBD
the/DT
highest/JJS
in/IN
patients/NNS
living/VBG
in/IN
Jeju/NN
Province/NN
(/(
8.4/CD
%/NN
)/)
./.
====================
Patients/NNS
aged/JJ
50–59/CD
years/NNS
showed/VBD
the/DT
highest/JJS
positivity/NN
rates/NNS
[/(
7/CD
]/)
./.
====================
Another/DT
study/NN
of/IN
surgical/JJ
specimens/NNS
revealed/VBD
that/IN
149/CD
of/IN
80,947/CD
cases/NNS
(/(
0.18/CD
%/NN
)/)
were/VBD
of/IN
parasitic/JJ
origin/NN
./.
====================
Of/IN
these/DT
,/,
112/CD
cases/NNS
were/VBD
cysticercosis/NN
involving/VBG
several/JJ
organs/NNS
,/,
most/JJS
commonly/RB
subcutaneous/JJ
tissues/NNS
and/CC
muscles/NNS
[/(
8/CD
]/)
./.
====================
From/IN
1993/CD
to/TO
2006/CD
,/,
a/DT
total/JJ
of/IN
74,448/CD
serum/NN
samples/NNS
obtained/VBN
from/IN
patients/NNS
with/IN
neurological/JJ
manifestations/NNS
and/CC
liver/NN
diseases/NNS
were/VBD
tested/VBN
by/IN
ELISA/NN
./.
====================
The/DT
percentage/NN
of/IN
samples/NNS
showing/VBG
high/JJ
antibody/NN
titers/NNS
against/IN
TsM/NN
cyst/NN
fluid/NN
(/(
CF/NN
)/)
antigen/NN
decreased/VBD
from/IN
8.3/CD
%/NN
to/TO
2.2/CD
%/NN
[/(
9/CD
]/)
,/,
which/WDT
indicated/VBD
that/IN
cysticercosis/NN
,/,
including/VBG
NC/NN
,/,
has/VBZ
continued/JJ
to/TO
occur/VB
in/IN
Korea/NN
,/,
although/IN
its/PRP$
incidence/NN
has/VBZ
substantially/RB
decreased/VBD
./.
====================
The/DT
symptoms/NNS
of/IN
NC/NN
vary/VBP
depending/VBG
on/IN
the/DT
number/NN
,/,
location/NN
,/,
and/CC
size/NN
of/IN
the/DT
infected/JJ
worm/NN
(/(
s/NNS
)/)
;/:
the/DT
duration/NN
of/IN
infection/NN
;/:
the/DT
evolutionary/JJ
stage/NN
of/IN
lesions/NNS
;/:
and/CC
the/DT
presence/NN
or/CC
absence/NN
of/IN
acephalic/JJ
budding/VBG
cysticercus/NN
[/(
10,11/CD
]/)
./.
====================
Major/JJ
symptoms/NNS
include/VBP
headache/NN
,/,
seizure/NN
,/,
paresis/NN
,/,
and/CC
focal/JJ
neurologic/JJ
deficits/VBZ
./.
====================
More/RBR
importantly/RB
,/,
NC/NN
is/VBZ
a/DT
leading/VBG
cause/VBP
of/IN
adult-onset/JJ
seizure/NN
in/IN
areas/NNS
where/WRB
the/DT
disease/NN
is/VBZ
endemic/JJ
[/(
1,12/NN
]/)
./.
====================
The/DT
accurate/JJ
diagnosis/NN
of/IN
NC/NN
is/VBZ
important/JJ
for/IN
effectively/RB
controlling/VBG
the/DT
disease/NN
./.
====================
The/DT
key/JJ
to/TO
the/DT
diagnosis/NN
of/IN
NC/NN
is/VBZ
interpreting/JJ
the/DT
patient/NN
’/CD
s/NNS
manifestations/NNS
together/RB
with/IN
data/NNS
provided/VBD
by/IN
radiological/JJ
findings/NNS
and/CC
immunological/JJ
tests/NNS
,/,
since/IN
the/DT
parasite/NN
’/CD
s/NNS
eggs/NNS
are/VBP
not/RB
present/JJ
in/IN
the/DT
patients/NNS
’/CD
stool/NN
./.
====================
Neuroimaging/VBG
diagnosis/NN
depends/VBZ
largely/RB
on/IN
computed/VBN
tomography/NN
(/(
CT/NN
)/)
and/or/CC
magnetic/JJ
resonance/NN
imaging/NN
(/(
MRI/NN
)/)
because/IN
a/DT
definitive/JJ
histological/JJ
diagnosis/NN
is/VBZ
neither/CC
possible/JJ
nor/CC
feasible/JJ
in/IN
many/JJ
cases/NNS
[/(
13,14/CD
]/)
./.
====================
However/RB
,/,
these/DT
methods/NNS
have/VBP
limitations/NNS
due/JJ
to/TO
the/DT
highly/RB
pleomorphic/JJ
presentation/NN
of/IN
NC/NN
,/,
overlapping/VBG
with/IN
that/DT
of/IN
other/JJ
intracranial/JJ
space-occupying/VBG
lesions/NNS
[/(
14,15/CD
]/)
./.
====================
Tests/NNS
to/TO
detect/VB
specific/JJ
antibodies/NNS
in/IN
the/DT
patient/NN
’/CD
s/NNS
serum/cerebrospinal/JJ
fluid/NN
(/(
CSF/NN
)/)
have/VBP
been/VBN
applied/VBN
to/TO
provide/VB
additional/JJ
evidence/NN
./.
====================
Immunodiagnosis/NN
might/MD
support/VB
other/JJ
diagnostic/JJ
procedures/NNS
for/IN
NC/NN
in/IN
neurological/JJ
patients/NNS
[/(
16,17/CD
]/)
./.
====================
Many/JJ
cases/NNS
of/IN
active-stage/NN
NC/NN
can/MD
be/VB
treated/VBN
with/IN
specific/JJ
chemotherapeutics/NNS
./.
====================
However/RB
,/,
chronic/JJ
NC/NN
and/CC
acephalic/JJ
cysticercosis/NN
in/IN
the/DT
ventricles/NNS
are/VBP
not/RB
susceptible/JJ
to/TO
anthelminthics/NNS
,/,
but/CC
should/MD
instead/RB
receive/JJ
surgical/JJ
or/CC
symptomatic/JJ
treatment/NN
,/,
such/JJ
as/IN
worm/NN
removal/NN
surgery/NN
,/,
anticonvulsants/NNS
,/,
analgesics/NNS
,/,
or/CC
shunt/VB
operations/NNS
to/TO
relieve/VB
the/DT
increased/VBN
intracranial/JJ
pressure/NN
or/CC
to/TO
control/JJ
intractable/JJ
seizures/VBZ
[/(
18/CD
]/)
./.
====================
Specific/JJ
treatment/NN
can/MD
shorten/VB
and/CC
diminish/VBP
the/DT
symptoms/NNS
caused/VBD
by/IN
inflammation/NN
associated/VBN
with/IN
active/JJ
NC/NN
,/,
and/CC
such/JJ
treatment/NN
appears/VBZ
to/TO
reduce/VB
the/DT
risk/NN
of/IN
headache/JJ
and/CC
late-recurring/JJ
refractory/JJ
seizure/NN
[/(
1,18/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
the/DT
mid-1980s/NNS
brought/VBN
dramatic/JJ
advances/NNS
in/IN
the/DT
management/NN
of/IN
NC/NN
./.
====================
Emerging/VBG
neuroimaging/VBG
techniques/NNS
greatly/RB
improved/JJ
the/DT
capability/NN
to/TO
diagnose/VB
organic/JJ
brain/NN
diseases/NNS
[/(
13,19/CD
]/)
./.
====================
The/DT
concomitant/JJ
application/NN
of/IN
serological/JJ
diagnoses/NNS
[/(
20,21/CD
]/)
provided/VBD
further/JJ
evidence/NN
for/IN
the/DT
presence/NN
of/IN
the/DT
worm/NN
in/IN
the/DT
brain/NN
./.
====================
Safe/JJ
and/CC
effective/JJ
chemotherapeutics/NNS
for/IN
the/DT
medical/JJ
treatment/NN
of/IN
NC/NN
were/VBD
successfully/RB
launched/VBN
[/(
22,23/CD
]/)
./.
====================
Several/JJ
molecular/JJ
and/CC
cell/NN
biological/JJ
studies/NNS
have/VBP
elucidated/VBN
bioactive/JJ
molecules/NNS
of/IN
TsM/NN
that/DT
are/VBP
crucially/RB
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
homeostatic/JJ
functions/NNS
[/(
24,25/CD
]/)
and/CC
the/DT
symbiotic/JJ
protein/NN
interactome/JJ
network/NN
of/IN
the/DT
worm/NN
[/(
26/CD
]/)
./.
====================
These/DT
efforts/NNS
have/VBP
made/VBN
the/DT
disease/NN
controllable/JJ
and/CC
manageable/JJ
./.
====================
However/RB
,/,
unsolved/JJ
problems/VBZ
remain/VBP
for/IN
the/DT
more/RBR
effective/JJ
management/JJ
of/IN
the/DT
disease/NN
,/,
such/JJ
as/IN
control/JJ
of/IN
intractable/JJ
seizures/VBZ
,/,
especially/RB
after/IN
medical/JJ
treatment/NN
;/:
the/DT
diagnosis/NN
of/IN
acephalic/JJ
cysticercosis/NN
in/IN
the/DT
ventricles/NNS
;/:
and/CC
the/DT
serological/JJ
diagnosis/NN
of/IN
early/JJ
infections/NNS
and/CC
patients/NNS
who/WP
are/VBP
infected/JJ
with/IN
relatively/RB
few/JJ
worms/NNS
in/IN
the/DT
CNS/NN
and/CC
other/JJ
areas/NNS
./.
====================
In/IN
this/DT
article/NN
,/,
we/PRP
briefly/RB
overview/NN
the/DT
advances/NNS
and/CC
current/JJ
status/NN
of/IN
the/DT
immunodiagnosis/NN
of/IN
NC/NN
in/IN
Korea/NN
./.
====================
As/IN
a/DT
first/JJ
step/NN
toward/IN
NC/NN
serodiagnosis/NN
,/,
an/DT
extensive/JJ
study/NN
to/TO
determine/VB
the/DT
applicability/NN
of/IN
ELISA/NN
employing/VBG
TsM/NN
CF/NN
as/IN
an/DT
antigen/NN
was/VBD
carried/VBN
out/RP
using/VBG
paired/JJ
samples/NNS
of/IN
serum/NN
and/CC
CSF/NN
from/IN
patients/NNS
with/IN
NC/NN
./.
====================
The/DT
overall/JJ
sensitivity/NN
and/CC
specificity/NN
were/VBD
90.1/CD
%/NN
and/CC
88.5/CD
%/NN
,/,
respectively/RB
./.
====================
CSF/NN
showed/VBD
greater/JJR
sensitivity/NN
./.
====================
This/DT
result/NN
demonstrated/VBD
that/IN
a/DT
serological/JJ
test/NN
using/VBG
paired/JJ
samples/NNS
of/IN
serum/NN
and/CC
CSF/NN
was/VBD
highly/RB
beneficial/JJ
for/IN
differentiating/VBG
NC/NN
from/IN
other/JJ
causes/VBZ
of/IN
organic/JJ
brain/NN
diseases/NNS
[/(
20/CD
]/)
./.
====================
To/TO
establish/VB
the/DT
appropriate/JJ
diagnostic/JJ
criteria/NNS
,/,
the/DT
specific/JJ
antibody/NN
levels/NNS
were/VBD
measured/VBN
in/IN
1:100/CD
diluted/VBN
serum/NN
(/(
in/IN
phosphate/NN
buffered/JJ
saline/NN
containing/VBG
0.05/CD
%/NN
Tween/CD
20/CD
)/)
and/CC
undiluted/JJ
CSF/NN
samples/NNS
from/IN
355/CD
patients/NNS
with/IN
several/JJ
neurological/JJ
diseases/NNS
,/,
including/VBG
NC/NN
./.
====================
The/DT
positive/JJ
criterion/NN
was/VBD
set/NN
as/IN
the/DT
low/JJ
limit/VB
of/IN
the/DT
positive/JJ
reaction/NN
,/,
which/WDT
was/VBD
also/RB
the/DT
mid-point/JJ
of/IN
the/DT
absorbance/NN
range/NN
of/IN
the/DT
lowest/JJS
frequency/NN
in/IN
serum/NN
samples/NNS
used/VBN
in/IN
the/DT
blind/JJ
test/NN
[/(
20/CD
]/)
./.
====================
Considering/VBG
that/WDT
the/DT
amount/NN
of/IN
specific/JJ
IgG/NN
might/MD
be/VB
1/100/CD
of/IN
the/DT
amount/NN
in/IN
serum/NN
[/(
27/CD
]/)
,/,
the/DT
same/JJ
positive/JJ
criterion/NN
could/MD
be/VB
applied/VBN
for/IN
CSF/NN
samples/NNS
./.
====================
Detection/NN
of/IN
specific/JJ
antibody/NN
levels/NNS
by/IN
ELISA/NN
either/CC
in/IN
serum/NN
or/CC
in/IN
CSF/NN
,/,
thereafter/RB
,/,
became/VBD
the/DT
main/JJ
mode/NN
of/IN
NC/NN
serodiagnosis/NN
./.
====================
IgG/NN
subclass/NN
responses/NNS
demonstrated/VBD
that/IN
sera/NNS
from/IN
patients/NNS
with/IN
NC/NN
reacted/VBD
mainly/RB
with/IN
the/DT
IgG4/NN
subclass/NN
[/(
28/CD
]/)
./.
====================
One/CD
of/IN
the/DT
critical/JJ
problems/NNS
encountered/VBN
in/IN
the/DT
serological/JJ
diagnosis/NN
of/IN
NC/NN
is/VBZ
the/DT
differential/JJ
diagnosis/NN
from/IN
other/JJ
parasitic/JJ
infections/NNS
./.
====================
Cross-reactions/NNS
that/DT
arise/VBP
from/IN
other/JJ
larval/JJ
cestodiases/NNS
,/,
such/JJ
as/IN
alveolar/JJ
and/CC
cystic/JJ
echinococcoses/NNS
(/(
AE/NN
and/CC
CE/NN
,/,
respectively/RB
)/)
,/,
and/CC
sparganosis/NN
should/MD
be/VB
ruled/VBN
out/IN
,/,
since/IN
these/DT
larval/JJ
cestodiases/NNS
frequently/RB
provoke/JJ
serological/JJ
cross-reactions/NNS
[/(
29/CD
]/)
./.
====================
For/IN
the/DT
serological/JJ
differentiation/NN
of/IN
NC/NN
from/IN
sparganosis/NN
,/,
the/DT
diagnostic/JJ
properties/NNS
of/IN
TsM/NN
CF/NN
proteins/NNS
were/VBD
compared/VBN
with/IN
those/DT
of/IN
parenchymal/JJ
extracts/NNS
./.
====================
CF/NN
showed/VBD
a/DT
higher/JJR
antibody/NN
detection/NN
capability/NN
than/IN
parenchymal/JJ
extracts/NNS
./.
====================
Sera/NNS
from/IN
NC/NN
patients/NNS
cross-reacted/VBD
with/IN
the/DT
sparganum/NN
extracts/NNS
,/,
and/CC
the/DT
TsM/NN
antigen/NN
showed/VBD
cross-reactions/NNS
to/TO
the/DT
sera/NNS
of/IN
patients/NNS
with/IN
sparganosis/NN
./.
====================
Approximately/RB
50/CD
%/NN
of/IN
the/DT
sera/NNS
from/IN
sparganosis/NN
patients/NNS
exhibited/VBD
cross-reactions/NNS
against/IN
TsM/NN
parenchymal/JJ
extracts/NNS
(/(
Fig/NN
./.
====================
1A/NN
and/CC
1B/NN
)/)
./.
====================
This/DT
finding/NN
suggested/VBD
that/IN
some/DT
NC/NN
patients/NNS
might/MD
produce/VB
IgG/NN
antibodies/NNS
against/IN
TsM/NN
antigenic/JJ
proteins/NNS
,/,
which/WDT
are/VBP
common/JJ
in/IN
sparganosis/NN
and/CC
non-specifically/RB
bind/VBP
to/TO
sparganum/VB
extracts/NNS
./.
====================
The/DT
antigenic/JJ
components/NNS
that/IN
caused/VBD
the/DT
cross-reaction/NN
were/VBD
not/RB
a/DT
single/JJ
protein/NN
,/,
but/CC
multiple/JJ
proteins/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
When/WRB
sera/NNS
from/IN
NC/NN
patients/NNS
were/VBD
examined/VBN
by/IN
immunoblot/NN
,/,
TsM/NN
CF/NN
exhibited/VBD
a/DT
variety/NN
of/IN
reaction/NN
patterns/NNS
./.
====================
Several/JJ
protein/NN
bands/NNS
revealed/VBD
positive/JJ
antibody/NN
responses/NNS
,/,
of/IN
which/WDT
the/DT
bands/NNS
at/IN
7/CD
,/,
10/CD
,/,
15/CD
,/,
20–40/CD
,/,
43/CD
,/,
64/CD
,/,
95/CD
,/,
106/CD
,/,
and/CC
160/CD
kDa/NN
were/VBD
strongly/RB
reactive/JJ
(/(
Fig/NN
./.
====================
1B/NN
,/,
panel/NN
CF/NN
)/)
./.
====================
The/DT
10/CD
kDa/NN
component/NN
showed/VBD
the/DT
strongest/JJS
reaction/NN
,/,
with/IN
84.6/CD
%/NN
of/IN
the/DT
samples/NNS
(/(
209/CD
of/IN
247/CD
)/)
being/VBG
positive/JJ
[/(
28/CD
]/)
./.
====================
Although/IN
the/DT
reaction/NN
pattern/NN
of/IN
the/DT
parenchymal/JJ
extracts/NNS
was/VBD
similar/JJ
to/TO
that/DT
of/IN
the/DT
CF/NN
,/,
more/RBR
numerous/JJ
bands/NNS
ranging/VBG
from/IN
43/CD
to/TO
100/CD
kDa/NN
were/VBD
reactive/JJ
with/IN
sera/NNS
from/IN
NC/NN
patients/NNS
./.
====================
In/IN
general/JJ
,/,
high-molecular-weight/JJ
proteins/NNS
above/IN
47/CD
kDa/NN
were/VBD
shown/VBN
to/TO
be/VB
cross-reactive/JJ
both/CC
with/IN
TsM/NN
parenchymal/JJ
extracts/NNS
and/CC
with/IN
sparganum/NN
extracts/NNS
,/,
while/IN
the/DT
low-molecular-weight/JJ
proteins/NNS
(/(
LMWPs/NNS
)/)
(/(
ranging/VBG
from/IN
7/CD
to/TO
24/CD
kDa/NN
)/)
in/IN
CF/NN
showed/VBD
specific/JJ
antibody/NN
reactions/NNS
./.
====================
Our/PRP$
research/NN
group/NN
observed/VBD
similar/JJ
results/NNS
for/IN
serological/JJ
cross-reactivity/NN
with/IN
AE/NN
and/CC
CE/NN
./.
====================
High-molecular-weight/JJ
proteins/NNS
typically/RB
revealed/VBD
cross-reactions/NNS
[/(
28,29/CD
]/)
./.
====================
Those/DT
antigenic/JJ
bands/NNS
did/VBD
not/RB
seem/VB
to/TO
be/VB
the/DT
same/JJ
molecules/NNS
as/IN
the/DT
major/JJ
antigenic/JJ
proteins/NNS
of/IN
TsM/NN
./.
====================
This/DT
result/NN
further/RB
suggested/VBD
that/IN
TsM/NN
CF/NN
is/VBZ
suitable/JJ
for/IN
the/DT
differential/JJ
diagnosis/NN
of/IN
cysticercosis/NN
from/IN
other/JJ
cestodiases/NNS
,/,
as/IN
well/RB
as/IN
better/RBR
than/IN
parenchymal/JJ
extracts/NNS
for/IN
the/DT
serodiagnosis/NN
of/IN
cysticercosis/NN
[/(
20,28/CD
]/)
./.
====================
The/DT
amount/NN
of/IN
the/DT
150/CD
kDa/NN
protein/NN
in/IN
CF/NN
was/VBD
measured/VBN
by/IN
antibody-sandwich/JJ
ELISA/NN
in/IN
serum/NN
and/CC
CSF/NN
samples/NNS
from/IN
NC/NN
patients/NNS
./.
====================
The/DT
capture/NN
antibodies/NNS
were/VBD
a/DT
rabbit/NN
anti-CF/JJ
antibody/NN
and/CC
a/DT
monoclonal/JJ
antibody/NN
against/IN
the/DT
150/CD
kDa/NN
protein/NN
./.
====================
The/DT
detection/NN
limit/VB
of/IN
the/DT
test/NN
was/VBD
8/CD
ng/mL/NN
of/IN
the/DT
protein/NN
./.
====================
The/DT
levels/NNS
of/IN
the/DT
protein/NN
in/IN
351/CD
sera/NNS
from/IN
255/CD
patients/NNS
(/(
55/CD
surgery-proven/VBN
cases/NNS
and/CC
200/CD
cases/NNS
diagnosed/VBD
by/IN
positive/JJ
antibody/NN
reactions/NNS
and/CC
pathognomonic/JJ
CT/MRI/NN
findings/NNS
)/)
were/VBD
below/IN
the/DT
sensitivity/NN
of/IN
the/DT
assay/NN
./.
====================
Of/IN
the/DT
276/CD
CSF/NN
samples/NNS
tested/VBN
,/,
31/CD
(/(
11.2/CD
%/NN
)/)
revealed/VBD
a/DT
detectable/JJ
range/NN
,/,
which/WDT
indicated/VBD
that/IN
the/DT
detection/NN
of/IN
antigenemia/JJ
might/MD
not/RB
be/VB
sensitive/JJ
enough/IN
to/TO
diagnose/VB
NC/NN
./.
====================
The/DT
150/CD
kDa/NN
protein/NN
appeared/VBD
in/IN
the/DT
CSF/NN
in/IN
situations/NNS
such/JJ
as/IN
2/CD
days/NNS
after/IN
praziquantel/NN
treatment/NN
,/,
or/CC
a/DT
patient/NN
infected/JJ
with/IN
a/DT
racemose/JJ
cysticercus/NN
with/IN
a/DT
degenerated/JJ
cyst/NN
wall/NN
./.
====================
The/DT
appearance/NN
of/IN
free/JJ
150/CD
kDa/NN
protein/NN
might/MD
be/VB
associated/VBN
with/IN
cyst/NN
wall/NN
rupture/NN
./.
====================
Either/DT
by/IN
drug/NN
treatment/NN
or/CC
by/IN
natural/JJ
degeneration/NN
of/IN
old/JJ
TsM/NN
,/,
CF/NN
proteins/NNS
might/MD
be/VB
released/VBN
into/IN
the/DT
CSF/NN
[/(
40/CD
]/)
./.
====================
Our/PRP$
research/NN
group/NN
assessed/VBD
changing/VBG
patterns/NNS
of/IN
specific/JJ
antibody/NN
levels/NNS
after/IN
medical/JJ
treatment/NN
./.
====================
A/DT
total/JJ
of/IN
69/CD
patients/NNS
with/IN
NC/NN
participated/JJ
in/IN
the/DT
study/NN
./.
====================
The/DT
intervals/NNS
and/CC
number/NN
of/IN
examinations/NNS
during/IN
the/DT
follow-up/JJ
period/NN
varied/VBD
according/VBG
to/TO
the/DT
patient/NN
(/(
up/RB
to/TO
22/CD
months/NNS
)/)
./.
====================
Serially-collected/JJ
serum/NN
and/CC
CSF/NN
samples/NNS
were/VBD
examined/VBN
simultaneously/RB
for/IN
their/PRP$
specific/JJ
IgG/NN
antibody/NN
levels/NNS
by/IN
ELISA/NN
using/VBG
a/DT
CF/NN
antigen/NN
./.
====================
Individual/JJ
patients/NNS
showed/VBD
a/DT
typical/JJ
pattern/NN
of/IN
specific/JJ
IgG/NN
antibody/NN
levels/NNS
after/IN
treatment/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
Within/IN
four-month/CD
post-treatment/JJ
,/,
the/DT
antibody/NN
levels/NNS
were/VBD
temporarily/RB
elevated/JJ
in/IN
both/CC
the/DT
serum/NN
and/CC
CSF/NN
in/IN
most/JJS
patients/NNS
./.
====================
However/RB
,/,
in/IN
some/DT
cases/NNS
,/,
antibody/NN
levels/NNS
steadily/RB
declined/VBD
after/IN
treatment/NN
./.
====================
Some/DT
samples/NNS
that/DT
showed/VBD
a/DT
negative/JJ
antibody/NN
reaction/NN
before/IN
treatment/NN
turned/JJ
out/RP
to/TO
be/VB
positive/JJ
after/IN
treatment/NN
./.
====================
This/DT
result/NN
suggested/VBD
that/IN
follow-up/JJ
examinations/NNS
could/MD
be/VB
beneficial/JJ
as/IN
a/DT
complementary/JJ
tool/NN
(/(
provocation/NN
test/NN
)/)
in/IN
serodiagnosis/NN
./.
====================
One/CD
to/TO
two/CD
months/NNS
were/VBD
considered/VBN
to/TO
be/VB
a/DT
sufficient/JJ
interval/JJ
for/IN
initial/JJ
follow-up/JJ
surveillance/NN
for/IN
that/DT
purpose/NN
[/(
41/CD
]/)
./.
====================
However/RB
,/,
at/IN
the/DT
22-month/JJ
follow-up/JJ
,/,
most/JJS
NC/NN
patients/NNS
with/IN
a/DT
long/JJ
history/JJ
did/VBD
not/RB
show/VB
any/DT
significant/JJ
changes/NNS
in/IN
specific/JJ
antibody/NN
levels/NNS
in/IN
either/CC
the/DT
serum/NN
or/CC
CSF/NN
./.
====================
These/DT
results/NNS
demonstrated/VBD
that/IN
yearly/RB
serologic/JJ
follow-up/JJ
should/MD
be/VB
continued/JJ
for/IN
at/IN
least/JJS
5/CD
years/NNS
after/IN
treatment/NN
to/TO
differentiate/VB
cured/VBN
patients/NNS
from/IN
chronic/JJ
patients/NNS
with/IN
slowly/RB
calcifying/JJ
lesions/NNS
./.
====================
NC/NN
,/,
a/DT
parasitic/JJ
disease/NN
caused/VBD
by/IN
infection/NN
of/IN
the/DT
CNS/NN
with/IN
the/DT
TsM/NN
,/,
poses/VBZ
formidable/JJ
global/JJ
public/JJ
health/NN
problems/NNS
and/CC
critically/RB
affects/VBZ
disability-adjusted/JJ
life/NN
years/NNS
./.
====================
NC/NN
has/VBZ
become/VBN
an/DT
emerging/VBG
or/CC
a/DT
re-emerging/JJ
disease/NN
in/IN
industrialized/VBN
countries/NNS
due/JJ
to/TO
an/DT
increasing/VBG
frequency/NN
of/IN
immigration/NN
from/IN
endemic/JJ
areas/NNS
./.
====================
The/DT
disease/NN
is/VBZ
now/RB
regarded/VBN
as/IN
one/CD
of/IN
the/DT
most/JJS
important/JJ
emerging/VBG
diseases/NNS
,/,
together/RB
with/IN
other/JJ
viral-/JJ
and/CC
drug-resistant/JJ
bacterial/JJ
infections/NNS
[/(
42/CD
]/)
./.
====================
NC/NN
caused/VBD
public/JJ
health/NN
concerns/VBZ
in/IN
Korea/NN
over/IN
the/DT
past/NN
several/JJ
decades/NNS
./.
====================
However/RB
,/,
dramatic/JJ
improvements/NNS
in/IN
control/NN
and/CC
management/NN
took/VBD
place/NN
during/IN
the/DT
mid-1980s/NNS
./.
====================
The/DT
introduction/NN
of/IN
CT/NN
and/CC
MRI/NN
greatly/RB
increased/VBD
the/DT
diagnostic/JJ
accuracy/NN
,/,
and/CC
the/DT
development/NN
of/IN
serodiagnostics/NNS
provided/VBD
supportive/JJ
or/CC
confirmatory/JJ
evidence/NN
for/IN
NC/NN
./.
====================
Several/JJ
investigations/NNS
have/VBP
shown/VBN
that/IN
the/DT
detection/NN
of/IN
LMWPs/NNS
of/IN
the/DT
150/CD
kDa/NN
and/CC
120/CD
kDa/NN
subunits/NNS
in/IN
either/CC
serum/NN
or/CC
CSF/NN
is/VBZ
a/DT
good/JJ
target/NN
for/IN
the/DT
diagnosis/NN
of/IN
active-stage/JJ
NC/NN
./.
====================
Recent/JJ
progress/NN
in/IN
NC/NN
serodiagnosis/NN
has/VBZ
resulted/VBD
in/IN
two/CD
different/JJ
types/NNS
of/IN
antigenic/JJ
platforms/NNS
./.
====================
One/CD
is/VBZ
a/DT
chimeric/JJ
protein/NN
fused/VBN
with/IN
defined/VBN
molecules/NNS
with/IN
different/JJ
epitope/NN
specificities/NNS
[/(
17/CD
]/)
,/,
and/CC
the/DT
other/JJ
is/VBZ
a/DT
multi-antigen/JJ
print/JJ
immunoassay/NN
that/DT
uses/VBZ
different/JJ
antigens/NNS
as/IN
a/DT
cocktail/NN
[/(
17,43/CD
]/)
./.
====================
Both/DT
of/IN
these/DT
regimens/NNS
exhibited/VBD
reliable/JJ
diagnostic/JJ
feasibility/NN
,/,
especially/RB
for/IN
the/DT
diagnosis/NN
of/IN
active-stage/NN
NC/NN
./.
====================
Diagnosing/VBG
active/JJ
NC/NN
is/VBZ
important/JJ
because/IN
it/PRP
allows/VBZ
treatment/NN
with/IN
specific/JJ
chemotherapeutics/NNS
,/,
while/IN
chronic-stage/NN
or/CC
acephalic/JJ
budding/VBG
cysticercosis/NN
in/IN
the/DT
ventricles/NNS
is/VBZ
not/RB
subject/VB
to/TO
anthelminthics/NNS
,/,
but/CC
requires/VBZ
surgical/JJ
or/CC
symptomatic/JJ
treatment/NN
to/TO
control/JJ
intractable/JJ
seizures/VBZ
./.
====================
All/DT
these/DT
efforts/NNS
have/VBP
made/VBN
NC/NN
controllable/JJ
and/CC
manageable/JJ
./.
====================
However/RB
,/,
further/RB
study/NN
is/VBZ
required/VBN
to/TO
find/VB
solutions/NNS
for/IN
the/DT
control/NN
of/IN
late-onset/JJ
intractable/JJ
seizures/VBZ
,/,
especially/RB
after/IN
medical/JJ
treatment/NN
,/,
and/CC
for/IN
the/DT
serological/JJ
diagnosis/NN
of/IN
NC/NN
patients/NNS
infected/JJ
with/IN
few/JJ
worms/NNS
./.
====================
Such/JJ
further/RBR
advances/NNS
would/MD
enhance/VB
the/DT
detection/NN
,/,
management/NN
,/,
and/CC
prevention/NN
of/IN
NC/NN
./.
====================
The/DT
identification/NN
and/CC
combing/VBG
of/IN
other/JJ
novel/JJ
antigenic/JJ
molecules/NNS
that/WDT
bear/VBP
different/JJ
epitope/NN
specificity/NN
will/MD
further/RBR
contribute/VB
to/TO
the/DT
design/NN
of/IN
final/JJ
platform/NN
regimen/NNS
(/(
s/NNS
)/)
./.
====================
(/(
A/DT
)/)
Scattergram/NN
of/IN
specific/JJ
antibody/NN
levels/NNS
in/IN
sera/NNS
from/IN
patients/NNS
with/IN
NC/NN
,/,
NC/NN
crossreacted/JJ
to/TO
the/DT
sparganum/NN
extracts/NNS
and/CC
sera/NNS
from/IN
patients/NNS
with/IN
sparganosis/NN
./.
====================
Serum/NN
samples/NNS
from/IN
NC/NN
cases/NNS
showed/VBD
the/DT
highest/JJS
levels/NNS
of/IN
reactivity/NN
against/IN
TsM/NN
CF/NN
./.
====================
Some/DT
sparganosis/NN
sera/NNS
revealed/VBD
cross-reactions/NNS
against/IN
TsM/NN
parenchymal/JJ
extracts/NNS
,/,
but/CC
showed/VBD
no/DT
crossreactions/NNS
against/IN
TsM/NN
CF/NN
./.
====================
(/(
B/NN
)/)
Immunoblot/NN
analysis/NN
of/IN
three/CD
different/JJ
antigens/NNS
(/(
TsM/NN
CF/NN
,/,
TsM/NN
parenchymal/JJ
extracts/NNS
,/,
and/CC
sparganum/NN
extracts/NNS
)/)
./.
====================
Lanes/NNS
a–c/JJ
,/,
sera/NNS
from/IN
NC/NN
patients/NNS
;/:
lanes/NNS
d–f/IN
,/,
sera/NNS
from/IN
sparganosis/NN
patients/NNS
;/:
lanes/NNS
g–i/NNS
,/,
sera/NNS
from/IN
NC/NN
cases/NNS
cross-reacted/VBD
with/IN
the/DT
sparganum/NN
extracts/NNS
,/,
lanes/NNS
j–l/NN
,/,
negative/JJ
controls/NNS
./.
====================
NC/NN
,/,
neurocysticercosis/NN
;/:
TsM/NN
,/,
Taenia/NN
solium/NN
metacestode/NN
;/:
CF/NN
,/,
cyst/NN
fluid/NN
;/:
Mr/NN
,/,
molecular/JJ
weights/NNS
in/IN
kDa/NN
./.
====================
Partial/JJ
purification/NN
of/IN
120/CD
and/CC
150/CD
kDa/NN
macromolecular/JJ
proteins/NNS
from/IN
TsM/NN
CF/NN
./.
====================
(/(
A/DT
)/)
A/DT
1.6/CD
×/NN
60/CD
cm/NN
long/JJ
FPLC/NN
packed/JJ
with/IN
Superdex/NN
200/CD
prep/NN
grade/NN
was/VBD
equilibrated/JJ
with/IN
20/CD
mM/NN
Tris-HCl/NN
(/(
pH/NN
8.0/CD
)/)
containing/VBG
150/CD
mM/NN
NaCl/NN
./.
====================
A/DT
total/JJ
of/IN
3/CD
mL/NN
(/(
10/CD
mg/NN
)/)
of/IN
TsM/NN
CF/NN
was/VBD
applied/VBN
to/TO
the/DT
column/NN
with/IN
a/DT
flow/NN
rate/NN
of/IN
0.5/CD
mL/min/NN
./.
====================
Eighty-five/JJ
fractions/NNS
(/(
1.5/CD
mL/NN
each/DT
)/)
were/VBD
analyzed/VBN
for/IN
their/PRP$
absorbance/NN
at/IN
280/CD
nm/NN
,/,
as/IN
monitored/VBN
by/IN
UNICORN/NN
(/(
v3.0/CD
)/)
./.
====================
(/(
B/NN
)/)
Analysis/NN
of/IN
the/DT
eluted/VBN
group/NN
III/CD
and/CC
IV/CD
proteins/NNS
by/IN
native/JJ
PAGE/NN
./.
====================
(/(
C/NN
)/)
Western/NN
blot/NN
analysis/NN
of/IN
the/DT
fraction/NN
III/CD
and/CC
IV/CD
proteins/NNS
probed/VBN
with/IN
anti-CF/JJ
antibody/NN
./.
====================
TsM/DT
,/,
Taenia/NN
solium/NN
metacestode/NN
;/:
CF/NN
,/,
cyst/NN
fluid/NN
;/:
FPLC/NN
,/,
fast-performance/NN
liquid/JJ
chromatography/NN
;/:
PAGE/NN
,/,
polyacrylamide/NN
gel/NN
electrophoresis/NN
;/:
Mr/NN
,/,
molecular/JJ
weights/NNS
in/IN
kDa/NN
;/:
SDS-PAGE/NN
,/,
sodium/NN
dodecyl/NN
sulfate–polyacrylamide/NN
gel/NN
electrophoresis/NN
./.
====================
Biophysical/JJ
properties/NNS
and/CC
phylogenetic/JJ
relationship/NN
of/IN
the/DT
120/CD
and/CC
150/CD
kDa/NN
proteins/NNS
of/IN
the/DT
TsM/NN
CF/NN
./.
====================
(/(
A/DT
)/)
The/DT
120/CD
kDa/NN
protein/NN
(/(
fraction/NN
IV/CD
)/)
was/VBD
separated/VBN
in/IN
a/DT
pH/NN
range/NN
of/IN
6–11/CD
,/,
after/IN
which/WDT
it/PRP
was/VBD
further/RBR
resolved/VBD
by/IN
15/CD
%/NN
SDS-PAGE/NN
./.
====================
The/DT
subunit/NN
proteins/NNS
of/IN
14/CD
,/,
16/CD
,/,
18/CD
,/,
22/CD
,/,
and/CC
28/CD
kDa/NN
,/,
which/WDT
were/VBD
identified/VBN
by/IN
proteome/JJ
analysis/NN
,/,
are/VBP
seen/VBN
./.
====================
(/(
B/NN
)/)
Phylogenetic/JJ
analysis/NN
demonstrated/VBD
that/IN
the/DT
subunits/NNS
of/IN
the/DT
120/CD
kDa/NN
macromolecule/NN
were/VBD
clustered/VBN
into/IN
two/CD
groups/NNS
of/IN
14/CD
and/CC
18/CD
kDa/NN
lineages/NNS
./.
====================
(/(
C/NN
)/)
2DE/NN
analysis/NN
of/IN
the/DT
150/CD
kDa/NN
protein/NN
(/(
fraction/NN
III/CD
)/)
./.
====================
The/DT
protein/NN
was/VBD
isoelectrically/RB
focused/VBN
using/VBG
IPGphor/NN
(/(
pH/NN
6–11/CD
)/)
,/,
after/IN
which/WDT
it/PRP
was/VBD
further/RBR
separated/VBN
by/IN
15/CD
%/NN
SDS-PAGE/NN
./.
====================
Each/DT
protein/NN
was/VBD
subjected/VBN
to/TO
MALDI-TOF/NN
analysis/NN
./.
====================
(/(
D/NN
)/)
Phylogenetic/JJ
analyses/NNS
of/IN
the/DT
subunit/NN
proteins/NNS
./.
====================
The/DT
representative/JJ
amino/NN
acid/NN
sequences/NNS
were/VBD
aligned/VBN
,/,
and/CC
optimized/VBN
with/IN
ClustalW/NN
and/CC
GeneDoc/NN
./.
====================
The/DT
phylogram/NN
was/VBD
constructed/VBN
with/IN
the/DT
neighborjoining/JJ
algorithm/NN
(/(
PHYLIP/NN
)/)
./.
====================
The/DT
statistical/JJ
significance/NN
of/IN
each/DT
branching/VBG
node/NN
was/VBD
evaluated/VBN
with/IN
1,000/CD
random/JJ
samples/NNS
./.
====================
TsM/DT
,/,
Taenia/NN
solium/NN
metacestode/NN
;/:
CF/NN
,/,
cyst/NN
fluid/NN
;/:
SDS-PAGE/NN
,/,
sodium/NN
dodecyl/NN
sulfate–polyacrylamide/NN
gel/NN
electrophoresis/NN
;/:
2DE/NNP
,/,
two-dimensional/JJ
electrophoresis/NN
;/:
MALDI-TOF/NN
,/,
matrix-assisted/VBD
laser/NN
desorption/NN
ionization/NN
time-of-flight/JJ
;/:
Mr/NN
,/,
molecular/JJ
weights/NNS
in/IN
kDa/NN
./.
====================
Immune/JJ
response/NN
of/IN
the/DT
representative/JJ
recombinant/JJ
proteins/NNS
derived/VBN
from/IN
the/DT
120/CD
and/CC
150/CD
kDa/NN
subunits/NNS
and/CC
chimera/NN
against/IN
sera/NNS
from/IN
active-stage/NN
NC/NN
patients/NNS
./.
====================
Each/DT
protein/NN
was/VBD
separated/VBN
by/IN
12/CD
%/NN
SDS-PAGE/NN
and/CC
transblotted/VBD
to/TO
a/DT
PVDF/NN
membrane/NN
./.
====================
The/DT
blots/NNS
were/VBD
incubated/VBN
with/IN
1:200/CD
diluted/VBD
individual/JJ
NC/NN
sera/NNS
overnight/JJ
./.
====================
The/DT
blots/NNS
were/VBD
further/RBR
incubated/VBN
with/IN
horseradish/JJ
peroxidase–conjugated/VBN
anti-human/JJ
IgG/NN
and/CC
developed/VBD
with/IN
4-chloro-1-/NN
naphthol/NN
as/IN
a/DT
chromogen/NN
./.
====================
NC/NN
,/,
neurocysticercosis/NN
;/:
SDS-PAGE/NN
,/,
sodium/NN
dodecyl/NN
sulfate–polyacrylamide/NN
gel/NN
electrophoresis/NN
;/:
PVDF/NN
,/,
polyvinylidene/NN
difluoride/JJ
./.
====================
Changing/VBG
patterns/NNS
of/IN
specific/JJ
IgG/NN
antibody/NN
levels/NNS
in/IN
serum/NN
and/CC
CSF/NN
samples/NNS
from/IN
the/DT
NC/NN
cases/NNS
after/IN
medical/JJ
treatment/NN
shown/VBN
by/IN
individual/JJ
patients/NNS
./.
====================
Acute/JJ
encephalitic/JJ
attacks/NNS
in/IN
each/DT
patient/NN
are/VBP
indicated/VBN
by/IN
red/JJ
arrows/VBZ
./.
====================
Significant/JJ
changes/NNS
of/IN
specific/JJ
IgG/NN
antibody/NN
levels/NNS
in/IN
either/CC
serum/NN
or/CC
CSF/NN
were/VBD
not/RB
observed/VBN
during/IN
the/DT
22-month/JJ
observation/NN
period/NN
./.
====================
CSF/NN
,/,
cerebrospinal/JJ
fluid/NN
;/:
NC/NN
,/,
neurocysticercosis/NN
./.
====================
